Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.9%.
The iShares Biotechnology ETF (IBB) eased 0.2%.
In corporate news, enGene (ENGN) shares fell past 7% after UBS downgraded the stock to neutral from buy and cut its price target to $7 from $34.
Moderna (MRNA) reported a Q4 loss of $2.91 per share, worse than the $2.83 loss expected in a FactSet poll. Revenue was $966 million, better than the consensus estimate of $942.8 million. Its shares gained about 4%.
OS Therapies (OSTX) shares jumped 12%. The firm said it signed agreements for the commercial-ready manufacturing of OST-HER2 to support anticipated Biologics Licensing Authorization filing.
West Pharmaceutical Services (WST) shares popped past 7%. Deutsche upgraded the stock to buy from hold while lowering its price target to $250 from $275.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。